BMS-Celgene Press Releases

Goals

Obtain press releases that are related to the BMS/Celgene merger on a broader scale.

Early Findings

BMS-Celgene Press Releases

Bristol-Myers and Celgene's Liso-Cel

BMS Investors' Bet


OTEZLA Divestiture

  • BMS has made it known that Celgene has reached a deal with Amgen.
  • Under the deal, the global license for OTEZLA® (apremilast) will be bought by Amgen for $13.4 billion.
  • This is linked to the acquisition of Celgene by BMS.
  • BMS has stated in the past that it has decided to sell off OTEZLA as part of an ongoing regulatory approval procedure.

Proposed next steps:

You need to be the project owner to select a next step.